NCT05217680View on ClinicalTrials.gov

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

PHASE3RecruitingINTERVENTIONAL
Enrollment

442

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Diabetic Macular Edema
Interventions
BIOLOGICAL

Bevacizumab

Administration of monthly intravitreal bevacizumab (4-12 injections)

BIOLOGICAL

Lucentis®

Administration of monthly intravitreal ranibizumab (4-12 injections)

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

Fundación Oftalmológica Nacional, Bogotá

06030

RECRUITING

SalaUno Salud, S.A.P.I. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT05217680 - Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema | Biotech Hunter | Biotech Hunter